Drug intelligence / Profile preview

DCB-BO1301

Development stage: Phase 2
Lead developer: Chung Mei Biopharma
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

DCB-BO1301 is an orally administered botanical extract under development for the treatment of advanced melanoma. It is being evaluated as an add-on therapy to dacarbazine, with clinical trials focused on determining its safety, tolerability, and efficacy in patients with advanced melanoma. The exact mechanism of action has not been fully elucidated, but it may inhibit the growth of certain types of tumor cells. The drug was initially developed by A2 Healthcare and is currently being developed by Chung Mei Biopharma[1][2][4].

Other names: botanical extract DCB-BO1301

Beyond the preview

Go deeper on DCB-BO1301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCB-BO1301.

Explore the full profile